Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Plus Raltitrexed vs Taxol in Second-line Advanced Gastric Cancer
NCT02072317Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of raltitrexed in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
raltitrexed
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02072317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072317.